Skip to main content

Table 4 Correlation between magnitude of increase in Lp(a) levels and MACE

From: Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease

 

Crude model

Adjusted model I

Adjusted model II

HR (95%CI)

p

HR (95%CI)

p

HR (95%CI)

p

Reference category (n = 181) ≤ 0 mg/dL

1

—

1

—

1

—

1st quartile (n = 90) > 0-2 mg/dL

1.57 (0.90–2.71)

0.111

1.72 (0.98–3.02)

0.058

1.63 (0.94–2.83)

0.084

2nd quartile (n = 64) > 2–4.1 mg/dL

1.59 (0.87–2.92)

0.134

1.65 (0.90–3.02)

0.109

1.56 (0.85–2.86)

0.151

3rd quartile (n = 77) > 4.1–10.1 mg/dL

0.78 (0.38–1.59)

0.488

0.78 (0.38–1.59)

0.485

0.73 (0.35–1.49)

0.381

4th quartile (n = 76) > 10.1 mg/dL

2.29 (1.36–3.84)

0.002

2.00 (1.18–3.42)

0.011

1.78 (0.97–3.28)

0.062

  1. Reference category: patients with an increase in Lp(a)
  2. 1st quartile: patients with an increase in Lp(a) level > 0-2 mg/dL
  3. 2nd quartile: > 2–4.1 mg/dL. 3rd quartile: > 4.1–10.1 mg/dL.4th quartile: > 10.1 mg/dL
  4. Adjusted model I: adjusted for baseline Lp(a) levels
  5. Adjusted model II:adjusted for on-statin Lp(a) levels